• Health
  • Science
  • U.S.
  • Technology
  • Business
  • World
  • Politics
  • Entertainment
  • Sports

Building a Better World

News and information

  • Home
  • Privacy Policy
  • Contact Us
  • Our Team

FDA approves new miracle treatment for asthma

March 24, 2016 By Sam Catherman

FDA approves new miracle treatment for asthma

The U.S. FDA has just approved a new medication, Reslizumab, that promises to tackle the most severe cases of asthma.

Severe asthma is a growing problem, affecting a staggering 8 percent of the American population in 2009. According to a report from Medscape, however, the U.S. FDA has just approved a new treatment, Reslizumab, also known as Cinqair, which promises to provide relief for the most severe cases of the respiratory disorder.

The drug, produced by Teva Pharmaceuticals, is a monoclonal antibody and was approved for patients 18 years and older. The treatment is geared toward patients whose condition is connected to elevated eosinophilis, a type of white blood cell linked to inflammation in the respiratory tract.

Reslizumab works to reduce the eosinophils levels in the blood. According to the FDA, roughly five percent of patients with asthma suffer from severe and uncontrolled attacks related to an eosinophilic phenotype, despite the best efforts of other types of treatments.

Reslizumab is administered every four weeks by an intravenous infusion in a supervised clinical setting to keep anaphylaxis under control. The FDA voted 11 to 3 to recommend the approval of the drug for adults suffering from severe asthma based on safety and efficiency numbers from a series of clinical tests. The panel passed a unanimous vote against approving the drug for children, however, due to a lack of available data.

The FDA carried out four double-blind, randomized, placebo-controlled trials to test reslizumab. They tested the drug on patients with severe asthma who were currently receiving the next best available treatments. Participants received either reslizumab or a placebo every four weeks in addition to the treatments the were already getting for their asthma.

The trials showed that people receiving reslizumab suffered fewer asthma attacks less frequently than patients who received a placebo. The people receiving the new medication also found it easier to exhale a higher volume of air than the patients who received a placebo.

Side effects of the treatment included muscle pain, cancer, and anaphylaxis, which the FDA warned could threaten the lives of patients taking the drug. Still, the treatment could offer relief to patients with severe asthma who were previously unable to find it.

A press release from the FDA describing the treatment can be found here.

 

Sharing

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Filed Under: Front Page, Health

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebookrss

Search:

Recent Posts

  • Shocking discovery in New Jersey stuns authorities April 22, 2018
  • Huge volcanic explosion could wipe out the United States April 21, 2018
  • Huge controversy erupts over world’s hottest pepper April 15, 2018
  • SpaceX is about to do something astonishing April 15, 2018
  • Massive breakthrough: Possible hearing loss cure discovered April 8, 2018
  • Scientists shocked by astonishing Mars photos April 8, 2018
  • Scientists shocked by massive dinosaur discovery April 7, 2018
  • Astonishing picture of New York will blow your mind April 7, 2018
  • No joke: This Viagra story will shock you March 31, 2018
  • Common over-the-counter medicine kills someone: stunning report March 31, 2018
  • This insane Dungeons and Dragons report will blow your mind March 25, 2018
  • Huge breakthrough: Simple trick to lose weight discovered March 24, 2018
  • Scientists uncover shocking truth about meat March 24, 2018
  • Huge discovery about humans floors scientists March 19, 2018
  • Astonishing Jupiter discovery totally floors scientists March 17, 2018


Copyright © 2018 Jones Kilmartin Group, LLC · Metro Pro Theme On Genesis Framework · WordPress